Latest News

Official Statement

Sep

02

2025

US NCI Sponsors Senhwa Biosciences’ Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma

Aug

07

2025

Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors

Jul

16

2025

Senhwa Biosciences Highlights Breakthroughs in Dual First-in-Class Drug Programs at Annual Shareholders’ Meeting Today

Jun

25

2025

Senhwa Biosciences Shines at G4thering 2025, Reinforcing Global Leadership and Driving International Cooperation

Jun

04

2025

Senhwa Biosciences Announces Positive Clinical Data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma.

Apr

02

2025

Senhwa Biosciences Recognized by European Media as One of Taiwan’s Most Noteworthy Biotech Companies in 2025

Mar

07

2025

Senhwa Biosciences Attended Cathay Securities' Institutional Investor Conference to Update the Company's Business Operations and Future Outlook

Dec

26

2024